loader image
Friday, October 10, 2025
78.6 F
McAllen
- Advertisement -

AG Paxton Sues Big Pharma for 1,000% Insulin Price Hike Conspiracy

Translate to Spanish or other 102 languages!

 Texas Attorney General Ken Paxton sued major insulin manufacturers and pharmacy benefit managers (“PBMs”)—including Eli Lilly, Express Scripts, CVS Pharmacy, and others—over a conspiracy to increase prices of insulin. Image for illustration purposes
 Texas Attorney General Ken Paxton sued major insulin manufacturers and pharmacy benefit managers (“PBMs”)—including Eli Lilly, Express Scripts, CVS Pharmacy, and others—over a conspiracy to increase prices of insulin. Image for illustration purposes
- Advertisement -

AUSTIN – Texas Attorney General Ken Paxton sued major insulin manufacturers and pharmacy benefit managers (“PBMs”)—including Eli Lilly, Express Scripts, CVS Pharmacy, and others—over a conspiracy to increase prices of insulin.

Through this conspiracy, the manufacturers artificially and willingly raised the prices of insulin then paid a significant, undisclosed portion back to the PBMs as a quid pro quo for inclusion in the PBMs’ standard offerings. The PBMs then granted preferred status to the manufacturer whose drug has the highest list price while excluding lower priced drugs. These synthetic insulin drugs, which today cost the manufacturers less than $2 to produce and were originally priced at $20 when released in the late 1990s, now range between $300 and $700. In the last decade alone, the manufacturers who are defendants in the lawsuit have increased the prices of their insulins up to 1,000%. Attorney General Paxton is suing because the insulin pricing scheme violates the Texas Deceptive Trade Practices Act, constitutes unjust enrichment, and represents an unlawful civil conspiracy.

“This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin. Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could,” said Attorney General Paxton. “These companies acted illegally and unethically to enrich themselves, and we will hold them accountable.”

- Advertisement -

According to the complaint, “While the PBM Defendants represent that they perform their services on behalf of their clients (including Texas payors) and diabetics to lower drug prices, increase access to affordable drugs, and promote diabetic health, these representations are false. Rather, the PBM Defendants have worked in coordination with the Manufacturer Defendants to distort the market for diabetic treatments to their benefit at the expense of Texas diabetics and payors.”

Liston & Deas, David Nutt & Associates, the Cicala Law Firm, and Foreman Watkins Krutz are serving as outside counsel.

To read the filing, click here.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Microplastics in the Gut Tied to Patterns Seen in Colorectal Cancer

Microplastics are common and consist of tiny pieces of plastic that are 5 millimeters (mm) or less. Recent study results, which have not been published in a peer-reviewed journal yet, show that how microplastics may impact bacteria in the human gut.

DHR Health Brownsville’s Fall Fest and Health Fair, Oct. 25th

DHR Health Brownsville invites the community to take charge of their health and celebrate the season in a very healthy way with their first ever Fall Fest and Health Fair. The event is set to take place from 8 a.m. to noon on October 25, 2025 at the DHR Health Brownsville Hospital located at 4750 North Expressway 77 in Brownsville. The event is free and open to the public.  

Dr. David G. Alonzo Reaches 1,000th da Vinci Robotic-Assisted Cancer Surgery Milestone

DHR Health Urologic Oncologist, Dr. David G. Alonzo, has successfully performed his 1,000th da Vinci robotic-assisted surgical procedure for the treatment of urologic cancers

Could Direct-to-Consumer Drug Pricing Compete with Prescription Insurance?

A new study offers a glimpse at how direct-to-consumer pharmacy pricing could one day present stiff competition to the private prescription drug insurance model, researchers say. 
- Advertisement -
×